ArticleOncogene2026
Decitabine suppresses triple-negative breast cancer by disrupting DNMT1 liquid-liquid phase separation and synergizes with G9a inhibition.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) remains a substantial clinical challenge due to the lack of well-defined therapeutic targets. Previous studies have demonstrated that epigenetic modifiers play crucial roles in the progression of various cancers. In this study, we identify DNA methyltransferase 1 (DNMT1) as a critical epigenetic driver of TNBC proliferation and metastasis. Our findings show that DNMT1 is highly expressed in TNBC and forms liquid-liquid phase separation (LLPS) condensates. Knockout of DNMT1 sensitizes TNBC cells to apoptosis and lipid peroxidation, downregulates oncogenic pathways, and upregulates apoptosis-related genes. The DNMT1 inhibitor decitabine (DAC) disrupts DNMT1 condensates, consequently inducing apoptosis and lipid peroxidation. Mechanistically, DAC directly binds to the disordered domain of DNMT1, thereby dissolving LLPS condensates and impairing epigenetic silencing. Remarkably, DAC synergizes with histone methyltransferase G9a inhibitor BIX-01294 (BIX) to suppress TNBC proliferation, migration, and invasion. Combined treatment with DAC and BIX significantly inhibits lung metastasis in murine and human TNBC mouse models, reducing proliferative cancer cells and metastatic burden. This study reveals DNMT1 LLPS as a druggable vulnerability in TNBC and establishes LLPS disruption as a promising therapeutic strategy, providing a rationale for combining epigenetic inhibitors to treat TNBC and other cancers with high DNMT1 expression.
Identifiers
42649369What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.